

Docket No. X-15950

-2-

Amendments to the Claims

Please cancel claims 36 - 90 and add new claims 91 - 137.

91. An isolated antibody, or antigen-binding portion thereof, that specifically binds human IL-1 β , wherein said antibody comprises:

- a) a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 39;
- b) a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2;
- c) a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 41;
- d) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 10;
- e) a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 21; and,
- f) a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 38.

92. The antibody of Claim 91 wherein said antibody comprises a heavy chain encoded by the amino acid sequence as shown in SEQ ID NO: 47 and a light chain encoded by the amino acid sequence as shown in SEQ ID NO: 48.

93. The antibody of Claim 91 wherein said antibody comprises a heavy chain encoded by the amino acid sequence as shown in SEQ ID NO: 68 and a light chain encoded by the amino acid sequence as shown in SEQ ID NO: 48.

94. An isolated antibody, or antigen-binding portion thereof, that specifically binds human IL-1 β , wherein said antibody comprises:

- a) a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 37;
- b) a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2;
- c) a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 15;
- d) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 10;
- e) a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 21; and,
- f) a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 35.

Docket No. X-15950

-3-

95. The antibody of Claim 94 wherein said antibody comprises a heavy chain encoded by the amino acid sequence as shown in SEQ ID NO: 45 and a light chain encoded by the amino acid sequence as shown in SEQ ID NO: 46.

96. An isolated antibody, or antigen-binding portion thereof, that specifically binds human IL-1 β , wherein said antibody comprises:

- a) a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 39;
- b) a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2;
- c) a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 17;
- d) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 10;
- e) a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 16; and,
- f) a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 36.

97. The antibody of Claim 96 wherein said antibody comprises a heavy chain encoded by the amino acid sequence as shown in SEQ ID NO: 49 and a light chain encoded by the amino acid sequence as shown in SEQ ID NO: 50.

98. An isolated antibody, or antigen-binding portion thereof, that specifically binds human IL-1 β , wherein said antibody comprises:

- a) a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 39;
- b) a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2;
- c) a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 17;
- d) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 10;
- e) a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 21; and,
- f) a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 35.

99. The antibody of Claim 98 wherein said antibody comprises a heavy chain encoded by the amino acid sequence as shown in SEQ ID NO: 51 and a light chain encoded by the amino acid sequence as shown in SEQ ID NO: 52.

Docket No. X-15950

-4-

100. An isolated antibody, or antigen-binding portion thereof, that specifically binds human IL-1 β , wherein said antibody comprises:

- a) a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29;
- b) a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2;
- c) a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 17;
- d) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 10;
- e) a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 21; and,
- f) a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 30.

101. The antibody of Claim 100 wherein said antibody comprises a heavy chain encoded by the amino acid sequence as shown in SEQ ID NO: 53 and a light chain encoded by the amino acid sequence as shown in SEQ ID NO: 54.

102. An isolated nucleic acid comprising a polynucleotide encoding the antibody or antigen binding portion thereof, of Claim 92.

103. An expression vector comprising a nucleic acid according to Claim 102.

104. A host cell stably transfected with the expression vector of Claim 103.

105. A process for producing an antibody or antigen binding portion thereof, comprising cultivating the host cell of Claim 104 and recovering the polypeptide encoded by said polynucleotide from the culture.

106. A pharmaceutical composition comprising the antibody or antigen binding portion thereof of Claim 92.

107. A method of treating rheumatoid arthritis or osteoarthritis, comprising administering to a patient in need thereof an effective amount of the antibody or antigen binding portion thereof, of Claim 92.

Docket No. X-15950

-5-

108. An isolated nucleic acid, comprising a polynucleotide encoding the antibody or antigen binding portion thereof, of Claim 93.

109. An expression vector comprising a nucleic acid according to Claim 108.

110. A host cell stably transfected with the expression vector of Claim 109.

111. A process for producing an antibody or antigen binding portion thereof, comprising cultivating the host cell of Claim 110 and recovering the polypeptide encoded by said polynucleotide from the culture.

112. A pharmaceutical composition comprising the antibody or antigen binding portion thereof of Claim 93.

113. A method of treating rheumatoid arthritis or osteoarthritis, comprising administering to a patient in need thereof an effective amount of the antibody or antigen binding portion thereof, of Claim 93.

114. An isolated nucleic acid, comprising a polynucleotide encoding the antibody or antigen binding portion thereof, of Claim 95.

115. An expression vector comprising a nucleic acid according to Claim 114.

116. A host cell stably transfected with the expression vector of Claim 115.

117. A process for producing an antibody or antigen binding portion thereof, comprising cultivating the host cell of Claim 116 and recovering the polypeptide encoded by said polynucleotide from the culture.

118. A pharmaceutical composition comprising the antibody or antigen binding portion thereof of Claim 95.

Docket No. X-15950

-6-

119. A method of treating rheumatoid arthritis or osteoarthritis, comprising administering to a patient in need thereof an effective amount of the antibody or antigen binding portion thereof, of Claim 95.

120. An isolated nucleic acid, comprising a polynucleotide encoding the antibody or antigen binding portion thereof, of Claim 97.

121. An expression vector comprising a nucleic acid according to Claim 120.

122. A host cell stably transfected with the expression vector of Claim 121.

123. A process for producing an antibody or antigen binding portion thereof, comprising cultivating the host cell of Claim 122 and recovering the polypeptide encoded by said polynucleotide from the culture.

124. A pharmaceutical composition comprising the antibody or antigen binding portion thereof of Claim 97.

125. A method of treating rheumatoid arthritis or osteoarthritis, comprising administering to a patient in need thereof an effective amount of the antibody or antigen binding portion thereof, of Claim 97.

126. An isolated nucleic acid, comprising a polynucleotide encoding the antibody or antigen binding portion thereof, of Claim 99.

127. An expression vector comprising a nucleic acid according to Claim 126.

128. A host cell stably transfected with the expression vector of Claim 127.

129. A process for producing an antibody or antigen binding portion thereof, comprising cultivating the host cell of Claim 128 and recovering the polypeptide encoded by said polynucleotide from the culture.

Docket No. X-15950

-7-

130. A pharmaceutical composition comprising the antibody or antigen binding portion thereof of Claim 99.

131. A method of treating rheumatoid arthritis or osteoarthritis, comprising administering to a patient in need thereof an effective amount of the antibody or antigen binding portion thereof, of Claim 99.

132. An isolated nucleic acid, comprising a polynucleotide encoding the antibody or antigen binding portion thereof, of Claim 101.

133. An expression vector comprising a nucleic acid according to Claim 132.

134. A host cell stably transfected with the expression vector of Claim 133.

135. A process for producing an antibody or antigen binding portion thereof, comprising cultivating the host cell of Claim 134 and recovering the polypeptide encoded by said polynucleotide from the culture.

136. A pharmaceutical composition comprising the antibody or antigen binding portion thereof of Claim 101.

137. A method of treating rheumatoid arthritis or osteoarthritis, comprising administering to a patient in need thereof an effective amount of the antibody or antigen binding portion thereof, of Claim 101.